cardiovascular disease
Recent randomized clinical trials have demonstrated that addition of niacin with laropiprant [a PGD<sub>2</sub>receptor subtype 1 (DP1) blocker] to statin-based therapies does not significantly decrease the risk of cardiovascular disease events, but increases the risk of serious adverse events.